HeartBeam’s AI algorithm shows equal performance on 3D and standard ECGs

SANTA CLARA - HeartBeam, Inc. (NASDAQ:BEAT), a micro-cap healthcare technology company with a market value of $46.32 million, announced new study results showing its deep learning algorithms performed equally well in detecting cardiac rhythms when applied to both the company’s 3D ECG system and standard 12-lead ECGs. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 2.98.

The study, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, compared ECG recordings from 201 patients using both HeartBeam’s system and standard 12-lead ECGs. The algorithms achieved 94.5% accuracy with HeartBeam’s device versus 95.5% with standard ECGs when detecting atrial fibrillation, atrial flutter, and sinus rhythm.

Researchers found no significant differences in accuracy between the two systems across 131 cases of sinus rhythm, 57 cases of atrial fibrillation, and 13 cases of atrial flutter.

"This study represents an exciting step forward in making advanced cardiac monitoring more user-friendly and widespread," said Rob Eno, Chief Executive Officer of HeartBeam, according to the company’s press release.

HeartBeam’s technology captures heart electrical signals from three distinct directions using a credit card-sized device, which the company claims can synthesize these signals into a 12-lead ECG. The company plans to use data from this study to support future FDA submissions for product enhancements.

HeartBeam received FDA clearance for arrhythmia assessment using its 3D ECG technology in December 2024, while its 12-lead ECG synthesis software remains under FDA review.

The study results suggest the company’s portable device might offer comparable performance to traditional ECG systems for certain rhythm detections, potentially enabling monitoring in settings where standard 12-lead ECGs are impractical.

In other recent news, HeartBeam Inc. reported its second-quarter 2025 earnings, showcasing a slight earnings per share (EPS) beat. The company achieved an EPS of -$0.15, surpassing the forecasted -$0.16. This 6.25% positive surprise was supported by strategic cost-cutting measures. Additionally, HeartBeam is preparing for a pilot commercial launch later this year, following the FDA 510(k) clearance for its arrhythmia assessment system. Benchmark has maintained a Speculative Buy rating on HeartBeam, with an $8.00 price target. This rating reflects confidence in the company’s progress, especially after the recent earnings report.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.